Mesoblast Limited Stock Price, News & Analysis (NASDAQ:MESO)

$4.92 -0.08 (-1.60 %)
(As of 11/24/2017 02:43 AM ET)
Previous Close$5.00
Today's Range$4.86 - $4.99
52-Week Range$4.39 - $12.50
Volume8,764 shs
Average Volume31,200 shs
Market Capitalization$428.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.7

About Mesoblast Limited (NASDAQ:MESO)

Mesoblast Limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MESO
  • Previous Symbol: OTCMKTS:MBLTY
  • CUSIPN/A
    Phone61-3-9639-6036

    Debt

    Debt-to-Equity RatioN/A
    Current Ratio3.53%
    Quick Ratio3.53%

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$2.41 million
    Price / Sales174.83
    Cash FlowN/A
    Price / CashN/A
    Book Value$6.53 per share
    Price / Book0.75

    Profitability

    Trailing EPS($0.78)
    Net Income$-76,810,000.00
    Net Margins-2,006.86%
    Return on Equity-12.04%
    Return on Assets-9.60%

    Miscellaneous

    Employees108
    Outstanding Shares85,640,000

    Frequently Asked Questions for Mesoblast Limited (NASDAQ:MESO)

    What is Mesoblast Limited's stock symbol?

    Mesoblast Limited trades on the NASDAQ under the ticker symbol "MESO."

    When will Mesoblast Limited make its next earnings announcement?

    Mesoblast Limited is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Mesoblast Limited.

    Where is Mesoblast Limited's stock going? Where will Mesoblast Limited's stock price be in 2017?

    6 brokerages have issued 12-month price targets for Mesoblast Limited's shares. Their predictions range from $8.50 to $20.00. On average, they anticipate Mesoblast Limited's stock price to reach $14.25 in the next twelve months. View Analyst Ratings for Mesoblast Limited.

    What are Wall Street analysts saying about Mesoblast Limited stock?

    Here are some recent quotes from research analysts about Mesoblast Limited stock:

    • 1. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (11/16/2017)
    • 2. Maxim Group analysts commented, "Mesoblast reported year-end (FYE June 30) with a net loss of $77M and ended the period with $46M in cash. The company completed a $40M raise on August 29, 2017 and currently has $84M in cash on the balance sheet." (8/30/2017)
    • 3. Cantor Fitzgerald analysts commented, "Accelerating Chronic Heart Failure (CHF). Mesoblast recently outlined its plans to seek a potential accelerated approval pathway for its MPC-150-IM product in patients with advanced cardiac heart failure. Based on the significant unmet need and serious complications of the disease, the company believes its 159-patient Phase 2b study with end-stage (Class IV) CHF patients that require left ventricular device (LVAD) assistance could support an accelerated approval. Completion of enrollment is imminent, and top-line data from the study are expected in 1Q18. The primary endpoint of the study will assess the number of times patients are able to undergo weaning off LVAD assistance. Enrolling in Advanced CHF. Mesoblast is also conducting a large 600-patient Phase 3 study in advanced (Class II/III) CHF patients that could serve as a confirmatory study and has enrolled over 400 patients so far. This study will assess recurrent, non-fatal, HF-related major adverse cardiac events between MPC-treated and sham-treated patients. Data are expected to be released in 2019. Attractive Markets. We estimate a large, multi-billion-dollar market for Mesoblast’s cell portfolio (combined royalties of ~$6 billion) when it reaches peak market penetration." (8/30/2017)

    Who are some of Mesoblast Limited's key competitors?

    Who are Mesoblast Limited's key executives?

    Mesoblast Limited's management team includes the folowing people:

    • Silviu Itescu, Chief Executive Officer, Executive Director
    • William A. Burns, Vice Chairman of the Board
    • Paul Hodgkinson, Group Chief Financial Officer
    • Peter Howard, General Counsel, Corporate Executive
    • John McMannis Ph.D., Head of Manufacturing
    • Paul Simmons Ph.D., Head of Research and New Product Development
    • Donna Skerrett M.D., Chief Medical Officer
    • Geraldine Storton MBA, Head of Regulatory Affairs and Quality Management
    • Charlie Harrison, Company Secretary
    • Brian Jamieson, Independent Non-Executive Chairman of the Board

    When did Mesoblast Limited IPO?

    (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

    How do I buy Mesoblast Limited stock?

    Shares of Mesoblast Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Mesoblast Limited's stock price today?

    One share of Mesoblast Limited stock can currently be purchased for approximately $4.92.

    How big of a company is Mesoblast Limited?

    Mesoblast Limited has a market capitalization of $428.22 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Mesoblast Limited employs 108 workers across the globe.

    How can I contact Mesoblast Limited?

    Mesoblast Limited's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


    MarketBeat Community Rating for Mesoblast Limited (MESO)

    Community Ranking:  3.0 out of 5 (star star star)
    Outperform Votes:  124 (Vote Outperform)
    Underperform Votes:  85 (Vote Underperform)
    Total Votes:  209
    MarketBeat's community ratings are surveys of what our community members think about Mesoblast Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Mesoblast Limited (NASDAQ:MESO)

      (How are Consensus Ratings Calculated?)
    Today30 Days Ago90 Days Ago180 Days Ago
    Consensus Rating: HoldHoldHoldHold
    Consensus Rating Score: 1.702.101.832.20
    Ratings Breakdown: 3 Sell Rating(s)
    3 Hold Rating(s)
    4 Buy Rating(s)
    0 Strong Buy Rating(s)
    2 Sell Rating(s)
    3 Hold Rating(s)
    5 Buy Rating(s)
    0 Strong Buy Rating(s)
    1 Sell Rating(s)
    3 Hold Rating(s)
    2 Buy Rating(s)
    0 Strong Buy Rating(s)
    0 Sell Rating(s)
    4 Hold Rating(s)
    1 Buy Rating(s)
    0 Strong Buy Rating(s)
    Consensus Price Target: $13.14$13.14$12.70$8.60
    Price Target Upside: 162.86% upside118.35% upside88.43% upside0.35% downside

    Consensus Price Target History for Mesoblast Limited (NASDAQ:MESO)

    Price Target History for Mesoblast Limited (NASDAQ:MESO)

    Analysts' Ratings History for Mesoblast Limited (NASDAQ:MESO)

    Show:
    DateFirmActionRatingPrice TargetImpact on Share PriceDetails
    11/15/2017Maxim GroupSet Price TargetBuy$14.00N/AView Rating Details
    11/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$16.00N/AView Rating Details
    8/31/2017CIBCInitiated CoverageOutperform -> Outperform$16.00HighView Rating Details
    8/30/2017Cantor FitzgeraldReiterated RatingBuy$20.00HighView Rating Details
    7/18/2017Credit Suisse GroupSet Price TargetHold$11.00LowView Rating Details
    4/3/2017ScotiabankReiterated RatingHold$8.50LowView Rating Details
    6/15/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
    2/25/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
    (Data available from 11/25/2015 forward)

    Earnings

    Earnings History for Mesoblast Limited (NASDAQ:MESO)


    No earnings announcements for this company have been tracked by MarketBeat.com

    Estimates

    Earnings Estimates for Mesoblast Limited (NASDAQ:MESO)
    2018 EPS Consensus Estimate: ($0.57)
    2019 EPS Consensus Estimate: ($0.54)
    QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
    Q2 20181($0.19)($0.19)($0.19)
    Q3 20181($0.19)($0.19)($0.19)
    Q4 20181($0.19)($0.19)($0.19)
    Q1 20191($0.19)($0.19)($0.19)
    Q2 20191($0.20)($0.20)($0.20)
    Q3 20191($0.21)($0.21)($0.21)
    Q4 20191$0.06$0.06$0.06
    (Data provided by Zacks Investment Research)

    Dividends

    Dividend History for Mesoblast Limited (NASDAQ:MESO)

    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading History for Mesoblast Limited (NASDAQ MESO)

    No insider trades for this company have been tracked by MarketBeat.com

    Headlines

    Latest Headlines for Mesoblast Limited (NASDAQ MESO)

    Source:
    DateHeadline
    Mesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald ForecastsMesoblast Limited (MESO) to Post FY2018 Earnings of ($0.80) Per Share, Cantor Fitzgerald Forecasts
    www.americanbankingnews.com - November 22 at 1:58 PM
    Financial Review: Mesoblast Limited (MESO) vs. Its PeersFinancial Review: Mesoblast Limited (MESO) vs. Its Peers
    www.americanbankingnews.com - November 21 at 2:12 PM
    Mesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by AnalystsMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Analysts
    www.americanbankingnews.com - November 21 at 8:24 AM
    Mesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. AnalystsMesoblast Limited (MESO) Given a $16.00 Price Target by Oppenheimer Holdings, Inc. Analysts
    www.americanbankingnews.com - November 19 at 10:20 PM
    Maxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price TargetMaxim Group Analysts Give Mesoblast Limited (MESO) a $14.00 Price Target
    www.americanbankingnews.com - November 19 at 5:38 PM
    Zacks Investment Research Lowers Mesoblast Limited (MESO) to Strong SellZacks Investment Research Lowers Mesoblast Limited (MESO) to Strong Sell
    www.americanbankingnews.com - November 18 at 10:52 PM
    Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)Mesoblast Limited Forecasted to Earn Q2 2018 Earnings of ($0.19) Per Share (MESO)
    www.americanbankingnews.com - November 17 at 11:52 PM
    Chairman’s Address to the Mesoblast 2017 Annual General MeetingChairman’s Address to the Mesoblast 2017 Annual General Meeting
    finance.yahoo.com - November 17 at 3:59 PM
    Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the First Quarter Ended September 30, 2017 - GlobeNewswire (press release)
    globenewswire.com - November 15 at 6:20 AM
    Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)Mesoblast to Host First Quarter Financial Results Webcast and Conference Call - GlobeNewswire (press release)
    globenewswire.com - November 15 at 6:20 AM
    Why Mesoblast limited remains a capital sinkhole - Motley Fool AustraliaWhy Mesoblast limited remains a capital sinkhole - Motley Fool Australia
    www.fool.com.au - November 15 at 6:20 AM
    Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)Reviewing Mesoblast Limited (MESO) & Protagonist Therapeutics (PTGX)
    www.americanbankingnews.com - November 14 at 1:36 PM
    Mesoblast to Host First Quarter Financial Results Webcast and Conference CallMesoblast to Host First Quarter Financial Results Webcast and Conference Call
    feeds.benzinga.com - November 13 at 5:49 PM
    Mesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable EffectsMesabi Trust (MESO) Phase 2 RA Trial Shows Early and Durable Effects
    www.streetinsider.com - November 12 at 6:21 AM
    Mesoblasts MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%Mesoblast's MPC therapy shows durable effect in mid-stage RA study; shares ahead 2%
    seekingalpha.com - November 12 at 6:21 AM
    BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTSBRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
    www.reuters.com - November 12 at 6:21 AM
    ETFs with exposure to Mesoblast Ltd. : November 6, 2017ETFs with exposure to Mesoblast Ltd. : November 6, 2017
    finance.yahoo.com - November 7 at 6:44 AM
    Mesoblast Limited (MESO) Receives Average Recommendation of "Hold" from BrokeragesMesoblast Limited (MESO) Receives Average Recommendation of "Hold" from Brokerages
    www.americanbankingnews.com - October 27 at 7:58 AM
    Here’s why the Mesoblast limited share price is getting slammed todayHere’s why the Mesoblast limited share price is getting slammed today
    www.fool.com.au - October 25 at 7:12 AM
    ETFs with exposure to Mesoblast Ltd. : October 23, 2017ETFs with exposure to Mesoblast Ltd. : October 23, 2017
    finance.yahoo.com - October 24 at 5:30 AM
    Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)Critical Analysis: Chromadex Corp (CDXC) vs. Mesoblast Limited (MESO)
    www.americanbankingnews.com - October 19 at 8:28 PM
    Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)Head to Head Analysis: Mesoblast Limited (MESO) versus Fibrocell Science (FCSC)
    www.americanbankingnews.com - October 16 at 10:30 AM
    ETFs with exposure to Mesoblast Ltd. : October 9, 2017ETFs with exposure to Mesoblast Ltd. : October 9, 2017
    finance.yahoo.com - October 9 at 4:06 PM
    Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017
    finance.yahoo.com - October 6 at 10:25 AM
    Mesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment ResearchMesoblast Limited (MESO) Upgraded to "Buy" by Zacks Investment Research
    www.americanbankingnews.com - October 5 at 12:26 AM
    Global Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty PaymentsGlobal Cell Therapy Market Report 2017-2021: Proliferation of Strategic Alliances and Royalty Payments
    www.finanznachrichten.de - October 4 at 7:33 AM
    Mesoblast Limited (MESO) Receives Consensus Rating of "Hold" from AnalystsMesoblast Limited (MESO) Receives Consensus Rating of "Hold" from Analysts
    www.americanbankingnews.com - October 2 at 4:32 AM
    Mesoblast Limiteds (MESO) "Buy" Rating Reaffirmed at Maxim GroupMesoblast Limited's (MESO) "Buy" Rating Reaffirmed at Maxim Group
    www.americanbankingnews.com - October 1 at 7:40 PM
    Research Analysts Offer Predictions for Mesoblast Limiteds Q1 2019 Earnings (MESO)Research Analysts Offer Predictions for Mesoblast Limited's Q1 2019 Earnings (MESO)
    www.americanbankingnews.com - September 29 at 1:52 PM
    Mesoblast Becomes Oversold (MESO)Mesoblast Becomes Oversold (MESO)
    www.thestreet.com - September 28 at 12:52 PM
    Clinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure Patients Completes EnrollmentClinical Trial of Mesoblast’s Cell Therapy in End-Stage Heart Failure Patients Completes Enrollment
    globenewswire.com - September 28 at 12:52 PM
    Mesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by BrokeragesMesoblast Limited (MESO) Given Consensus Recommendation of "Hold" by Brokerages
    www.americanbankingnews.com - September 7 at 4:46 AM
    ETFs with exposure to Mesoblast Ltd. : September 6, 2017ETFs with exposure to Mesoblast Ltd. : September 6, 2017
    finance.yahoo.com - September 5 at 10:09 PM
    Head-To-Head Contrast: Mesoblast Limited (MESO) versus Organovo Holdings (ONVO)Head-To-Head Contrast: Mesoblast Limited (MESO) versus Organovo Holdings (ONVO)
    www.americanbankingnews.com - September 4 at 4:06 PM
    Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
    finance.yahoo.com - September 2 at 6:14 AM
    Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Mesoblast Ltd. :MESO-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
    finance.yahoo.com - September 2 at 6:14 AM
    Mesoblast Limited to Post FY2018 Earnings of ($1.16) Per Share, Cantor Fitzgerald Forecasts (MESO)Mesoblast Limited to Post FY2018 Earnings of ($1.16) Per Share, Cantor Fitzgerald Forecasts (MESO)
    www.americanbankingnews.com - September 1 at 11:52 AM
    CIBC Initiates Coverage on Mesoblast limited (MESO)CIBC Initiates Coverage on Mesoblast limited (MESO)
    www.americanbankingnews.com - August 31 at 2:32 PM
    Mesoblast limited (MESO) Research Coverage Started at Oppenheimer Holdings, Inc.Mesoblast limited (MESO) Research Coverage Started at Oppenheimer Holdings, Inc.
    www.americanbankingnews.com - August 31 at 9:50 AM
    UPDATE: Oppenheimer Starts Mesoblast Limited (MESO) at Outperform - StreetInsider.comUPDATE: Oppenheimer Starts Mesoblast Limited (MESO) at Outperform - StreetInsider.com
    www.streetinsider.com - August 31 at 7:11 AM
    Mesoblast Limited (MESO) Given a $14.00 Price Target at Maxim GroupMesoblast Limited (MESO) Given a $14.00 Price Target at Maxim Group
    www.americanbankingnews.com - August 30 at 11:16 AM
    Mesoblast (MESO) Says it Completed Institutional Entitlement Offer for Fully Underwritten A$50.7M Capital Raise - StreetInsider.comMesoblast (MESO) Says it Completed Institutional Entitlement Offer for Fully Underwritten A$50.7M Capital Raise - StreetInsider.com
    www.streetinsider.com - August 30 at 6:29 AM
    Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 - GlobeNewswire (press release)Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 - GlobeNewswire (press release)
    globenewswire.com - August 30 at 6:29 AM
    Mesoblast Limited looks a long way from take off - Motley Fool AustraliaMesoblast Limited looks a long way from take off - Motley Fool Australia
    www.fool.com.au - August 30 at 6:29 AM
    Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017
    finance.yahoo.com - August 30 at 6:29 AM
    Why the Mesoblast limited share price plunged 10% this morning - Motley Fool AustraliaWhy the Mesoblast limited share price plunged 10% this morning - Motley Fool Australia
    www.fool.com.au - August 29 at 1:30 AM
    Mesoblast launches A$50.7M equity offering to existing shareholdersMesoblast launches A$50.7M equity offering to existing shareholders
    seekingalpha.com - August 27 at 12:59 AM
    Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)
    globenewswire.com - August 25 at 8:24 AM
    Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure - GlobeNewswire (press release)
    globenewswire.com - August 25 at 8:24 AM
    Cantor Fitzgerald Reiterates Buy Rating for Mesoblast Limited (MESO)Cantor Fitzgerald Reiterates Buy Rating for Mesoblast Limited (MESO)
    www.americanbankingnews.com - August 23 at 9:30 AM

    Social Media

    Financials

    Chart

    Mesoblast Limited (NASDAQ MESO) Chart for Saturday, November, 25, 2017
    Loading chart…

    This page was last updated on 11/25/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.